Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MK-6482 dose comparison in advanced renal cell carcinoma
MOH_2020-08-18_009041Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belzutifan in renal cell carcinoma (RCC) (2 arms), sponsored by Merck & Co. Started Aug 2020; status: completed.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2020-08-18_009041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-18_009041.